Project Grant RF1NS142814
Award Date
6/15/25
Completion Date
5/31/27
Dollars Obligated
$780K
Funding Federal Agency
National Institute on Aging
Awarding Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
This $451,000 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to develop tools to identify genes on human chromosome 21 that contribute to Down syndrome pathologies. The award recipient, The University of Texas Southwestern Medical Center, will use CRISPR interference technology and induced pluripotent stem cells derived from individuals with Down syndrome to conduct high-throughput...
This Project Grant award, issued by the National Institute on Aging (under CFDA 93.866 - Aging Research), provides $195,041 to the University of Pittsburgh to develop innovative statistical methods for understanding the relationship between co-occurring medical conditions, such as cardiovascular disease, and Alzheimer's disease risk in individuals with Down syndrome. The project aims to utilize data from the Alzheimer's Biomarker Consortium for Down Syndrome (ABC-DS) to explore...
The National Institutes of Health Trans-NIH Research Support program awarded a $4,010,262 Project Grant to the University of Illinois to study the role of amyloid precursor protein in neurogenesis and Alzheimer's disease pathology in Down syndrome. The three-year grant will support research examining how overexpression of amyloid precursor protein, which is located on chromosome 21 and thus triplicated in Down syndrome, impacts neural stem cell proliferation, neuronal differentiation, and...
The University of California, San Diego (UCSD) was awarded a $1,698,323 Project Grant from the National Institute on Aging (CFDA 93.866 Aging Research) to develop and validate a mouse model for Alzheimer's disease in Down syndrome (DS-AD). The goal is to create a genetically modified mouse that replicates key pathological features of DS-AD, including amyloid plaques, congophilic angiopathy, and neurofibrillary tangles. In the initial R61 phase, the researchers will demonstrate feasibility,...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Trustees of Columbia University in the City of New York provides $452,375 to investigate the potential use of the APLP1 protein as an early biomarker for Alzheimer's disease in individuals with Down syndrome. The project aims to leverage recent findings linking endosomal trafficking defects to the early pathology of Alzheimer's disease, which is observed decades before classical...
This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $804,450 provides funding to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, to investigate the mechanisms behind selective neuronal dysfunction caused by the Alzheimer's disease genetic risk factor ApoE4. The research aims to 1) validate the protective effects of the protein NELL2 in hippocampal excitatory neurons of ApoE4 mouse models,...
This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to gain a mechanistic understanding of the role of cellular senescence in the pathogenesis of Alzheimer's disease (AD). The $460,625 grant will fund research at the University of Massachusetts Medical School to dissect the separate P53/P21 and P16 senescence pathways and their functional consequences in AD using human induced pluripotent stem cell-based models. The 2-year project will produce...